Volume 3 Supplement 3
New perspectives in hereditary angioderma: Molecular mechanisms and therapeutic choices
Meeting report
-
Citation: World Allergy Organization Journal 2010 3(Suppl 3):223
-
The Pathophysiology of Hereditary Angioedema
Hereditary angioedema (HAE) causes recurrent episodes of angioedema that may be very severe and are frequently associated with significant morbidity and even mortality. Understanding the pathophysiology of thi...
Citation: World Allergy Organization Journal 2010 3(Suppl 3):224 -
Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema
Agents for prophylaxis of hereditary angioedema (HAE) have been available in the United States for several decades, but their usefulness is limited by side effects and they cannot be used at all in some patien...
Citation: World Allergy Organization Journal 2010 3(Suppl 3):225 -
Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism
Current strategies for the treatment of hereditary angioedema (HAE) include targeted inhibition or antagonism of the contact system, which is dysregulated in HAE patients by a C1 esterase inhibitor deficiency....
Citation: World Allergy Organization Journal 2010 3(Suppl 3):226 -
Summary and Conclusions: New Perspectives in Hereditary Angioedema: Molecular Mechanisms and Therapeutic Choices: A CME Symposium Presented at the World Allergy Congress, Buenos Aires, Argentina (December 2009)
Citation: World Allergy Organization Journal 2010 3(Suppl 3):227